Diagnosis and treatment of multiple sclerosis: a review

MP McGinley, CH Goldschmidt, AD Rae-Grant - Jama, 2021 - jamanetwork.com
Importance Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease
of the central nervous system characterized by inflammatory demyelination with axonal …

Treatment of multiple sclerosis: a review

SL Hauser, BAC Cree - The American journal of medicine, 2020 - Elsevier
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of
the central nervous system, and the leading cause of nontraumatic neurological disability in …

Neutrophil membrane‐camouflaged polyprodrug nanomedicine for inflammation suppression in ischemic stroke therapy

Y Zhao, Q Li, J Niu, E Guo, C Zhao, J Zhang… - Advanced …, 2024 - Wiley Online Library
Neuroinflammation has emerged as a major concern in ischemic stroke therapy because it
exacebates neurological dysfunction and suppresses neurological recovery after …

Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions

MP McGinley, JA Cohen - The Lancet, 2021 - thelancet.com
Summary The sphingosine 1-phosphate (S1P) signalling pathways have important and
diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for …

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

X Montalban, R Gold, AJ Thompson… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Sphingolipid metabolism in cancer signalling and therapy

B Ogretmen - Nature Reviews Cancer, 2018 - nature.com
Sphingolipids, including the two central bioactive lipids ceramide and sphingosine-1-
phosphate (S1P), have opposing roles in regulating cancer cell death and survival …

Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis

JWL Brown, A Coles, D Horakova, E Havrdova… - Jama, 2019 - jamanetwork.com
Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

J Kuhle, H Kropshofer, DA Haering, U Kundu… - Neurology, 2019 - neurology.org
Objective To assess the value of blood neurofilament light chain (NfL) as a biomarker of
recent, ongoing, and future disease activity and tissue damage and its utility to monitor …

Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies

G Luna, P Al**, J Burman, K Fink… - JAMA …, 2020 - jamanetwork.com
Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS)
have been associated with an increased risk of infections vs injectable therapies interferon …

Thinking outside the box: non-canonical targets in multiple sclerosis

L Bierhansl, HP Hartung, O Aktas, T Ruck… - Nature reviews Drug …, 2022 - nature.com
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that
causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …